Results 171 to 180 of about 32,790 (255)

Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors. [PDF]

J Histochem Cytochem, 2018
Ando K, Tohme YH, Srinivasiah A, Taylor-Parker J, Harrington Y, Shah AK, Oki E, Brahmandam M, Bharti AK.   +8 more
europepmc   +1 more source

Topoisomerase I Inhibitor LMP400 [PDF]

, 2020
openaire   +1 more source

Mode of Action Study of Novel DNA Non-intercalative Topoisomerase IIα Catalytic Inhibitors and PARP Inhibitors

, 2019
Part I: Mode of Action Study of Novel DNA Non-intercalative Topoisomerase IIα Catalytic Inhibitors DNA는 복제 시 이중나선의 구조적 특성으로 인해 한쪽이 풀리면 다른 쪽이 더욱더 엉키게 된다. 토포아이소머라아제는 엉킨 부분의 DNA를 단일 가닥 또는 이중 가닥 모두를 절단하고 재연결하여 위상학적인 문제를 해결하는 효소이다. 토포아이소머라아제는 크게 두 가지 종류가 있다.
장혜진
core  

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. [PDF]

J Natl Cancer Inst, 2018
McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P.   +27 more
europepmc   +1 more source

Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays. [PDF]

Sci Rep, 2018
Sandhaus S, Chapagain PP, Tse-Dinh YC.
europepmc   +1 more source

Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters. [PDF]

PLoS One, 2018
Temesszentandrási-Ambrus C, Tóth S, Verma R, Bánhegyi P, Szabadkai I, Baska F, Szántai-Kis C, Hartkoorn RC, Lingerfelt MA, Sarkadi B, Szakács G, Őrfi L, Nagaraja V, Ekins S, Telbisz Á.   +14 more
europepmc   +1 more source

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. [PDF]

Clin Cancer Res, 2018
Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.   +30 more
europepmc   +1 more source

Rezatapopt and the Return of Targetable p53

MedComm, Volume 7, Issue 7, July 2026.
Yuanze Luo, Assam El‐Osta
wiley   +1 more source

Ligand-based Pharmacophore Modeling, Virtual Screening and Molecular Docking Studies for Discovery of Potential Topoisomerase I Inhibitors. [PDF]

Comput Struct Biotechnol J, 2019
Pal S, Kumar V, Kundu B, Bhattacharya D, Preethy N, Reddy MP, Talukdar A.   +6 more
europepmc   +1 more source

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant <i>Ube3a</i> gene associated with Angelman syndrome. [PDF]

Mol Autism, 2018
Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD.   +5 more
europepmc   +1 more source